Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Oncology has recently undergone a revolutionary change with widespread adoption of immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in immunology Jg. 40; H. 6; S. 511 - 523
Hauptverfasser:	Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.06.2019 Elsevier Limited
Schlagworte:	Adaptive immunity Antigens Autoimmune diseases autoimmunity Cancer immunotherapy Cancer therapies checkpoint blockade Clinical trials Cloning Cytotoxicity Disease Etiology Hepatitis Immune checkpoint Immune system immune-related adverse events Immunoglobulins Immunotherapy Inflammatory bowel disease Inflammatory diseases Lymphocytes Lymphocytes T Melanoma Monoclonal antibodies Oncology tolerance Viral infections checkpoint blockade autoimmunity tolerance cancer immunotherapy immune-related adverse events
ISSN:	1471-4906, 1471-4981, 1471-4981
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!